Not Even Tripping

JRT: The LSD Analogue That Repairs the Brain Without the Trip

Published April 2026

Imagine a molecule that delivers many of the powerful therapeutic benefits associated with LSD — rapid brain repair, new neural connections, and potent antidepressant effects — but without the intense hallucinations. Sounds like science fiction? It's not. Researchers at the University of California, Davis have created exactly that: a groundbreaking compound called (+)-JRT.

The Breakthrough: By slightly altering the molecular structure of LSD, scientists have decoupled the "trip" from the "healing," opening doors for patients who previously couldn't risk psychedelic treatment.

The "Tire Rotation" That Changed Everything

Lead researcher Dr. David E. Olson, director of the UC Davis Institute for Psychedelics and Neurotherapeutics, described the innovation in delightfully simple terms: they performed the molecular equivalent of a “tire rotation.”

“By just transposing two atoms in LSD, we significantly improved JRT’s selectivity profile and reduced its hallucinogenic potential.”

JRT is a structural analogue of LSD where the embedded tryptamine core is converted to an isotryptamine version. Essentially, by swapping the positions of a carbon and a nitrogen atom, the overall shape remains nearly identical, but the way it interacts with serotonin receptors is fundamentally transformed.

What the Preclinical Studies Show

In cell and mouse studies, JRT demonstrated remarkable results that could redefine neuro-psychiatry:

+46% Dendritic spine density increase in the prefrontal cortex.
100x More potent antidepressant-like effects than ketamine in specific assays.
0 Head-twitch responses (hallucinogenic markers) observed in mouse models.

Why This Matters for Schizophrenia and Beyond

Traditional psychedelics like LSD are generally avoided for schizophrenia because they can worsen hallucinations. JRT’s design aims to sidestep that risk while harnessing the “psychoplastogenic” effects — the ability to promote structural and functional brain repair.

Researchers believe compounds like JRT could one day treat a wide range of conditions characterized by synaptic loss, including:

  • Depression and treatment-resistant depression
  • PTSD and trauma-related disorders
  • Schizophrenia (especially negative/cognitive symptoms)
  • Neurodegenerative diseases like Alzheimer’s and Parkinson’s
  • Stroke and traumatic brain injury

Important Caveats

It is important to note that this research is currently in the preclinical stage. While the results in mice are staggering, human clinical trials are the necessary next step to confirm safety and dosing. However, JRT represents a masterclass in rational drug design—engineering out side effects while keeping the cure.

The Future of Brain Repair

If JRT succeeds in human trials, it could transform mental health care. Instead of highly supervised, day-long psychedelic sessions, patients might one day take a medicine that quietly helps the brain rebuild itself while they go about their daily lives.

What do you think? Could non-hallucinogenic neuroplastogens be the next big leap in psychiatry? Share your thoughts in the comments below.

Disclaimer: This post is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for medical concerns.

Sources: PNAS Publication, UC Davis Institute for Psychedelics and Neurotherapeutics.

Comments

Popular posts from this blog

Fabian Society

Hidden Mold, Invisible Monsters — Mycotoxins Can Wreck You

Beat The Heat Even On The Street